Agomelatine for the treatment of generalized anxiety disorder

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

(2017) Dan J. Stein et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Pharmacokinetic evaluation of pregabalin for the treatment of generalized anxiety disorder

(2017) Massimiliano Buoli et al.   Expert Opinion on Drug Metabolism & Toxicology

Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder

(2017) Stewart A. Shankman et al.   JOURNAL OF CLINICAL PSYCHIATRY

Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study

(2017) Tsz-tai Chan et al.   Psychogeriatrics

Agomelatine-induced thrombocytopenic purpura, a possible new adverse effect

(2017) Delphine Bourneau-Martin et al.   THERAPIE

Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study

(2017) Tsz-tai Chan et al.   Psychogeriatrics

Is There a Role for Agomelatine in the Treatment of Anxiety Disorders? A Review of Published Data

(2017) D. De Berardis et al.   INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY

Effect of agomelatine on memory deficits and hippocampal gene expression induced by chronic social defeat stress in mice

(2017) Vincent Martin et al.   Scientific Reports

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

(2016) Gabriel Perlemuter et al.   CNS DRUGS

Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA)

(2016) Ta-Chuan Yeh et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Pharmacokinetic evaluation of fluvoxamine for the treatment of anxiety disorders

(2015) Alfredo Carlo Altamura et al.   Expert Opinion on Drug Metabolism & Toxicology

Pharmacological treatment for generalized anxiety disorder in adults: an update

(2015) Jennifer A Reinhold et al.   EXPERT OPINION ON PHARMACOTHERAPY

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression

(2015) Domenico De Berardis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale

(2015) Angel L Montejo et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Generalized Anxiety Disorder

(2015) Murray B. Stein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Valproic Acid–Induced Thrombocytopenia May Cause Wound Nonhealing in Individuals With Schizophrenia

(2015) Yu-Ting Tseng et al.   PSYCHOSOMATICS

Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety Disorder

(2014) Rachel Hershenberg et al.   CNS DRUGS

Agomelatine in the Treatment of Major Depressive Disorder: An Assessment of Benefits and Risks

(2014) Maximilian Gahr   Current Neuropharmacology

Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder

(2014) Massimiliano Buoli et al.   Expert Opinion on Drug Metabolism & Toxicology

Agomelatine: a new option for treatment of depression?

(2014) Chi-Un Pae   EXPERT OPINION ON PHARMACOTHERAPY

Cardiovascular adverse effects of newer antidepressants

(2014) Rajnish Mago et al.   Expert Review of Neurotherapeutics

Evaluation of the Effects of Therapeutic and Supratherapeutic Doses of Agomelatine on the QT/QTc Interval

(2014) Yves Donazzolo et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Agomelatine in Generalized Anxiety Disorder

(2014) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHIATRY

Antidepressant-Induced Liver Injury: A Review for Clinicians

(2013) Cosmin Sebastian Voican et al.   AMERICAN JOURNAL OF PSYCHIATRY

Agomelatine-induced gynaecomastia

(2013) Hui Ling Tan   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive-compulsive disorder

(2013) Bernardo Dell'Osso et al.   Early Intervention in Psychiatry

New approaches to the pharmacological management of generalized anxiety disorder

(2013) Massimiliano Buoli et al.   EXPERT OPINION ON PHARMACOTHERAPY

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice

(2013) Domenico De Berardis et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Agomelatinin İndüklediği Makülopapüler Döküntü: Bir Olgu Sunumu

(2013) Aslıhan OKAN İBİLOĞLU et al.   Noropsikiyatri Arsivi-Archives of Neuropsychiatry

Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study

(2013) Michele Fornaro et al.   Neuropsychiatric Disease and Treatment

Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach

(2012) A. Carlo Altamura et al.   CLINICAL DRUG INVESTIGATION

Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study

(2012) Cristina Dobrea et al.   Expert Opinion On Drug Safety

Guidelines for the pharmacological treatment of anxiety disorders, obsessive–compulsive disorder and posttraumatic stress disorder in primary care

(2012) Borwin Bandelow et al.   INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE

Agomelatine Prevents Relapse in Generalized Anxiety Disorder

(2012) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHIATRY

Agomelatine-Induced Akathisia with Concomitant Duloxetine Medication: A Case Report

(2012) C. Imboden et al.   PHARMACOPSYCHIATRY

Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder

(2011) Alfredo Carlo Altamura et al.   INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Humanistic and economic burden of generalized anxiety disorder in North America and Europe

(2011) Dennis A. Revicki et al.   JOURNAL OF AFFECTIVE DISORDERS

A Systematic, Updated Review on the Antidepressant Agomelatine Focusing on its Melatonergic Modulation

(2010) Michele Fornaro et al.   Current Neuropharmacology

Review: The importance of early symptom relief in antidepressant treatment: focus on agomelatine

(2010) Raymond W Lam   JOURNAL OF PSYCHOPHARMACOLOGY

Can We Prevent Fatal Liver Failure under Valproate?

(2010) M. M. Schmid et al.   PHARMACOPSYCHIATRY

Slow vs standard up-titration of paroxetine in the treatment of panic disorder: A prospective randomized trial

(2010) Massimiliano Buoli et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults

(2010) Robert Howland   Neuropsychiatric Disease and Treatment

Extreme Creatine Phosphokinase Elevation in a 20-Year-Old Man Participating in a Clinical Trail of Major Depressive Disorder

(2009) Thomas M. Shiovitz et al.   JOURNAL OF CLINICAL PSYCHIATRY

Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system

(2008) Luis San et al.   EUROPEAN PSYCHIATRY

Efficacy of Agomelatine in Generalized Anxiety Disorder

(2008) Dan J. Stein et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR

(2008) Sidney H. Kennedy et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY